Drug Profile
TERN 101
Alternative Names: TERN-101Latest Information Update: 13 Aug 2023
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Developer Terns Pharmaceuticals
- Class Carboxylic acids; Chlorobenzenes; Cyclopropanes; Hepatoprotectants; Indoles; Isoxazoles; Piperidines; Small molecules
- Mechanism of Action Farnesoid X-activated receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Non-alcoholic steatohepatitis
Most Recent Events
- 08 Aug 2023 Efficacy and adverse events data from a phase IIa trial in Non-alcoholic steatohepatitis released by Terns Pharmaceuticals
- 10 Jul 2023 Terns Pharmaceuticals completes a phase IIa DUET trial in Non-alcoholic steatohepatitis (Combination therapy) in USA (PO) (NCT05415722)
- 21 Jun 2023 Pharmacodynamics data from preclinical study in Non-alcoholic steatohepatitis presented at the European Association for the Study of the Liver Congress 2023 (EASl-2023)